Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 351 to 400 of 410

Guidance and quality standards awaiting development
Title	Type
Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]	Technology appraisal guidance
Thyroid disease	Quality standard
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [ID6724]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tinnitus	Quality standard
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]	Technology appraisal guidance
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]	Technology appraisal guidance
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733]	Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]	Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer at high risk of recurrence [ID6708]	Technology appraisal guidance
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis [ID1396]	Technology appraisal guidance
Tozorakimab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease [ID6711]	Technology appraisal guidance
Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids	HealthTech guidance
Transverse tibial transport for diabetic foot ulceration	HealthTech guidance
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]	Technology appraisal guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]	Technology appraisal guidance
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]	Technology appraisal guidance
Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]	Technology appraisal guidance
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]	Technology appraisal guidance
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]	Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]	Technology appraisal guidance
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]	Technology appraisal guidance
Troriluzole for spinocerebellar ataxia [ID6456]	Technology appraisal guidance
Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]	Technology appraisal guidance
Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [ID6755]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]	Technology appraisal guidance
Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]	Technology appraisal guidance
Upadacitinib for treating moderately to severely active systemic lupus erythematosus [TSID12366]	Technology appraisal guidance
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]	Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]	Technology appraisal guidance
Veligrotug for treating thyroid eye disease [ID6636]	Technology appraisal guidance
Venglustat for treating Fabry disease	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance
Vertebral body tethering for idiopathic scoliosis in children and young people	HealthTech guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]	Technology appraisal guidance
Vonaprument for treating geographic atrophy caused by age-related macular degeneration	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
Vulnerable populations: strategies for tackling inequalities	Quality standard
VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]	Technology appraisal guidance
Xanomeline tartrate–trospium chloride for treating psychosis associated with Alzheimer's disease	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]	Technology appraisal guidance

Results per page

10
25
50
All